As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
8 Analysts have issued a Atea Pharmaceuticals Inc forecast:
8 Analysts have issued a Atea Pharmaceuticals Inc forecast:
| Jun '25 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | - - | 
         
    -
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | -145 -145 | 
         
      
        
        15%
      
      
        
        15%
      
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -145 -145 | 
         
      
        
        15%
      
      
        
        15%
      
 
        
       | 
      |
| Net Profit | -136 -136 | 
         
      
        
        23%
      
      
        
        23%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
| Head office | United States | 
| CEO | Jean-Pierre Sommadossi | 
| Employees | 56 | 
| Founded | 2012 | 
| Website | ateapharma.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


